UH3HD108053
Cooperative Agreement
Overview
Grant Description
Large-scale implementation of community co-led maternal sepsis care practices to reduce morbidity and mortality from maternal infection - In the United States, infection is now the most common cause of direct maternal mortality and the third leading cause overall after cardiovascular conditions and other pre-existing medical conditions.
Nationally, there has been no improvement in the overall percentage of deaths from infection since 1987 when the CDC began maternal mortality surveillance, despite improvements in overall sepsis care for nonpregnant patients.
The long-term goal is to reduce maternal morbidity and mortality from maternal sepsis. The central hypothesis is that through community leadership, addressing barriers, and intensive implementation of standardized pregnancy-adjusted screening, diagnosis, and treatment, maternal morbidity from infection and sepsis will decrease.
The overall objectives in this application are to (I) identify patient-based and clinician-based barriers; (II) refine sepsis screening in pregnancy; and (III) implement a large-scale quality improvement collaborative.
The central hypothesis will be tested by pursuing the following specific aims: UG3 Phase 1) develop and support a maternal sepsis community leadership group of community representatives, patients, patient advocates, and survivors and family members of those who did not survive to inform and engage substantively throughout the study; 2A) identify patient-based barriers to care for severe maternal infection and sepsis; 2B) design strategies to implement evidence-based sepsis care interventions, specifically targeted to address and overcome barriers identified in aims 2A and 2B; 3) establish test characteristics of a pregnancy-adjusted intrapartum sepsis screen.
Once barriers have been identified with strategies to overcome them and the sepsis screening, diagnosis, and treatment care practices have been adjusted based on qualitative and quantitative data, it will be transitioned to the UH3 phase. UH3 Aim 1) identify clinician-based barriers to implementation; 2C) implement refined sepsis screening, diagnostic, and treatment care practices in California and Michigan and evaluate outcomes of maternal morbidity and mortality.
The research proposed in this application is innovative because it is one of the first studies to co-lead a large-scale maternal initiative with representatives from the community, diversity, equity and inclusion (DEI), patient advocate representatives, and patients and families with lived experience with sepsis.
This research is significant because it is expected that by identifying and addressing barriers to care and implementation through community, clinician, patient, and DEI partnerships, this large-scale implementation initiative will serve as a national model to reduce maternal mortality and morbidity from sepsis, and potentially serve as a model to address other causes of mortality.
Nationally, there has been no improvement in the overall percentage of deaths from infection since 1987 when the CDC began maternal mortality surveillance, despite improvements in overall sepsis care for nonpregnant patients.
The long-term goal is to reduce maternal morbidity and mortality from maternal sepsis. The central hypothesis is that through community leadership, addressing barriers, and intensive implementation of standardized pregnancy-adjusted screening, diagnosis, and treatment, maternal morbidity from infection and sepsis will decrease.
The overall objectives in this application are to (I) identify patient-based and clinician-based barriers; (II) refine sepsis screening in pregnancy; and (III) implement a large-scale quality improvement collaborative.
The central hypothesis will be tested by pursuing the following specific aims: UG3 Phase 1) develop and support a maternal sepsis community leadership group of community representatives, patients, patient advocates, and survivors and family members of those who did not survive to inform and engage substantively throughout the study; 2A) identify patient-based barriers to care for severe maternal infection and sepsis; 2B) design strategies to implement evidence-based sepsis care interventions, specifically targeted to address and overcome barriers identified in aims 2A and 2B; 3) establish test characteristics of a pregnancy-adjusted intrapartum sepsis screen.
Once barriers have been identified with strategies to overcome them and the sepsis screening, diagnosis, and treatment care practices have been adjusted based on qualitative and quantitative data, it will be transitioned to the UH3 phase. UH3 Aim 1) identify clinician-based barriers to implementation; 2C) implement refined sepsis screening, diagnostic, and treatment care practices in California and Michigan and evaluate outcomes of maternal morbidity and mortality.
The research proposed in this application is innovative because it is one of the first studies to co-lead a large-scale maternal initiative with representatives from the community, diversity, equity and inclusion (DEI), patient advocate representatives, and patients and families with lived experience with sepsis.
This research is significant because it is expected that by identifying and addressing barriers to care and implementation through community, clinician, patient, and DEI partnerships, this large-scale implementation initiative will serve as a national model to reduce maternal mortality and morbidity from sepsis, and potentially serve as a model to address other causes of mortality.
Awardee
Funding Goals
TO CONDUCT AND SUPPORT LABORATORY RESEARCH, CLINICAL TRIALS, AND STUDIES WITH PEOPLE THAT EXPLORE HEALTH PROCESSES. NICHD RESEARCHERS EXAMINE GROWTH AND DEVELOPMENT, BIOLOGIC AND REPRODUCTIVE FUNCTIONS, BEHAVIOR PATTERNS, AND POPULATION DYNAMICS TO PROTECT AND MAINTAIN THE HEALTH OF ALL PEOPLE. TO EXAMINE THE IMPACT OF DISABILITIES, DISEASES, AND DEFECTS ON THE LIVES OF INDIVIDUALS. WITH THIS INFORMATION, THE NICHD HOPES TO RESTORE, INCREASE, AND MAXIMIZE THE CAPABILITIES OF PEOPLE AFFECTED BY DISEASE AND INJURY. TO SPONSOR TRAINING PROGRAMS FOR SCIENTISTS, DOCTORS, AND RESEARCHERS TO ENSURE THAT NICHD RESEARCH CAN CONTINUE. BY TRAINING THESE PROFESSIONALS IN THE LATEST RESEARCH METHODS AND TECHNOLOGIES, THE NICHD WILL BE ABLE TO CONDUCT ITS RESEARCH AND MAKE HEALTH RESEARCH PROGRESS UNTIL ALL CHILDREN, ADULTS, FAMILIES, AND POPULATIONS ENJOY GOOD HEALTH. THE MISSION OF THE NICHD IS TO ENSURE THAT EVERY PERSON IS BORN HEALTHY AND WANTED, THAT WOMEN SUFFER NO HARMFUL EFFECTS FROM REPRODUCTIVE PROCESSES, AND THAT ALL CHILDREN HAVE THE CHANCE TO ACHIEVE THEIR FULL POTENTIAL FOR HEALTHY AND PRODUCTIVE LIVES, FREE FROM DISEASE OR DISABILITY, AND TO ENSURE THE HEALTH, PRODUCTIVITY, INDEPENDENCE, AND WELL-BEING OF ALL PEOPLE THROUGH OPTIMAL REHABILITATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Durham,
North Carolina
277054640
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 187% from $1,249,869 to $3,581,262.
Duke University was awarded
Community-Led Maternal Sepsis Care Initiative for Reduced Mortality
Cooperative Agreement UH3HD108053
worth $3,581,262
from the National Institute of Child Health and Human Development in September 2021 with work to be completed primarily in Durham North Carolina United States.
The grant
has a duration of 4 years 9 months and
was awarded through assistance program 93.865 Child Health and Human Development Extramural Research.
The Cooperative Agreement was awarded through grant opportunity Community Engaged Research on Pregnancy Related and Associated Infections and Sepsis Morbidity and Mortality (UG3/UH3 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 9/24/25
Period of Performance
9/30/21
Start Date
6/30/26
End Date
Funding Split
$3.6M
Federal Obligation
$0.0
Non-Federal Obligation
$3.6M
Total Obligated
Activity Timeline
Transaction History
Modifications to UH3HD108053
Additional Detail
Award ID FAIN
UH3HD108053
SAI Number
UH3HD108053-1098995866
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NT00 NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development
Funding Office
75NT00 NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development
Awardee UEI
TP7EK8DZV6N5
Awardee CAGE
4B478
Performance District
NC-04
Senators
Thom Tillis
Ted Budd
Ted Budd
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
National Institute of Child Health and Human Development, National Institutes of Health, Health and Human Services (075-0844) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,249,869 | 100% |
Modified: 9/24/25